Figure S2 from CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

2026 Open access

Read full text
Authors: Szu-Aun Long, Haley Todd, Grace Goodhart, Wen-Hsuan Chang, Amber M. Amparo, Rachel Bridgens, Julien Dilly, Se Jun Park, Robert M. Beal, Sara M. Shehadeh, Megan A. Satyadi, Vidushi K. Trivedi
+13 more Sarah E. Ackermann, Raivath Mukherjee, Craig M. Goodwin, A. Tudor Edwards, Clint A. Stalnecker, Kenneth D. Greis, Andrew J. Aguirre, G. Aaron Hobbs, Kirsten L. Bryant, Syed Kamran Ahmad, Adrienne D. Cox, Channing J. Der, Andrew M. Waters
DOI: 10.1158/0008-5472.31345623
Cited by: 0

Abstract

Pharmacologic validation of expected hits. KRAS-mutant PDAC cell lines were treated with various items

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Protein Kinase Regulation and GTPase Signaling CRISPR and Genetic Engineering

Publication details

Publication date
16 February 2026
Language
EN